Related Experiment Video
Updated: Jan 17, 2026

The Tail Suspension Test
Published on: January 28, 2012
Sodium-Glucose Cotransporter 2 Inhibitors for Lithium-Associated Kidney Dysfunction in Mood Disorders: A Real-World
Mete Ercis1, Idil Tarikogullari1, Vanessa K Pazdernik2
1Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
Introduction:
Sodium-glucose cotransporter-2 inhibitors (SGLT2i), initially developed for type 2 diabetes, have shown promise in improving renal outcomes in patients with and without diabetes. However, their effect on lithium-associated kidney dysfunction remains unknown.
Methods:
This historical cohort study included patients from Mayo Clinic (2001-2023) with mood disorders who received lithium for ≥6 months and later used SGLT2i for ≥1 month. Data on SGLT2i use and lithium treatment were extracted from electronic health records. Serum creatinine values were used to calculate estimated glomerular filtration rate (eGFR) trajectories. Linear mixed-effects models with piecewise linear splines were used to estimate eGFR slopes before and after SGLT2i initiation, adjusted for age and sex.
Results:
Fifty-six patients (mean age 57.4 years, 46.4% female), predominantly with bipolar disorder (86%), were included. The mean eGFR, measured nearest to SGLT2i initiation, was 77.9±26.0 mL/min/1.73 m2, and the mean duration of SGLT2i use was 19.5±17.8 months. Before SGLT2i initiation, eGFR declined at a rate of -1.43 mL/min/1.73 m2 per year (p<0.001). After initiation, eGFR increased by 0.69 mL/min/1.73 m2 per year, reflecting a +2.13 change (p=0.025). Sensitivity analyses, including only patients on lithium at SGLT2i initiation (n=22) or who had >1 year of SGLT2i use (n=29) showed similar, though non-significant, changes in slopes.
Conclusion:
SGLT2i treatment was associated with a significant improvement in eGFR trajectory in patients with mood disorders who received long-term lithium therapy. These findings suggest a potential role for SGLT2is in mitigating lithium-associated kidney dysfunction and highlight the need for randomized controlled trials in this population.
Insights
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improved kidney function in patients with mood disorders on lithium. This suggests SGLT2i may help prevent lithium-induced kidney damage.
Area of Science:
- Nephrology
- Psychiatry
- Pharmacology
Background:
- Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are used for type 2 diabetes and show renal benefits.
- The impact of SGLT2i on lithium-associated kidney dysfunction is unknown.
Purpose of the Study:
- To investigate the effect of SGLT2i on estimated glomerular filtration rate (eGFR) in patients with mood disorders receiving long-term lithium therapy.
Main Methods:
- Historical cohort study at Mayo Clinic (2001-2023).
- Included patients with mood disorders on lithium (≥6 months) and SGLT2i (≥1 month).
- Analyzed eGFR trajectories using linear mixed-effects models before and after SGLT2i initiation.
Main Results:
- Fifty-six patients were included (mean age 57.4 years).
- Before SGLT2i, eGFR declined by -1.43 mL/min/1.73 m²/year.
- After SGLT2i initiation, eGFR increased by 0.69 mL/min/1.73 m²/year (p=0.025).
Conclusions:
- SGLT2i treatment was associated with improved eGFR trajectory in patients on long-term lithium.
- SGLT2i may mitigate lithium-associated kidney dysfunction.
- Randomized controlled trials are needed to confirm these findings.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Antihypertensive Drugs: Potassium-Sparing Diuretics
Secondary Active Transport
Secondary Active Transport

